VivoSeq
Other

Oligodendroglioma

18

Pipeline Programs↗

7

Active Trials↗

11

Companies Involved↗

Oligodendroglioma is an emerging landscape with 18 programs across 11 companies. The most active players are Eli Lilly, Iovance Biotherapeutics, Inc., Pfizer. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

67/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Sanofi logo

Sanofi

3 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

20programs
Small molecule1155%
Monoclonal antibody315%
Vaccine315%
Protein / enzyme210%
Cell therapy15%

Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

10

clinical trials

Not yet recruiting3 · 30%
Recruiting2 · 20%
Active, not recruiting2 · 20%
Completed2 · 20%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05512351·80 enrolled
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Recruiting·HHospices Civils de Lyon·Phase 3·NCT04702581·280 enrolled
Abemaciclib in Patients with Oligodendroglioma
Active, not recruiting·SStephen Bagley, MD, MSCE·Phase 2·NCT03969706·10 enrolled
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Active, not recruiting·UUniversity of Florida·Phase 1·NCT06254326·12 enrolled
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Not yet recruiting·IInstitut de Recherches Internationales Servier (I.R.I.S.)·Phase 2·NCT07286292·10 enrolled
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
Not yet recruiting·SServier (Tianjin) Pharmaceutical Co. LTD.·N/A·NCT06969352·60 enrolled
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Not yet recruiting·—·Phase 2·NCT07120984·52 enrolled
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004024·60 enrolled
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Completed·GGrupo Español de Investigación en Neurooncología·Phase 2·NCT02530320·34 enrolled
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Terminated·—·Phase 2·NCT00003472·13 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)